Delving into the Latest Updates on Changzhou Yinsheng Pharmaceutical Co., Ltd with Synapse

Overview

Tags

Infectious Diseases

Digestive System Disorders

Respiratory Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	3

Top 5 Drug Type	Count

Small molecule drug	3

Top 5 Target	Count

NS4B(Nonstructural protein 4B)	1
NS5A(Nonstructural protein 5A)	1

主要目的：评估JDB0131 苯磺酸盐片在药物敏感性肺结核患者体内早期杀菌活性；探索最佳有效剂量，为IIb 期临床试验提供依据。次要目的： 1、评估JDB0131 苯磺酸盐片多次给药后在药物敏感性肺结核患者体内安全性和耐受性； 2、评估JDB0131 苯磺酸盐片多次给药后在药物敏感性肺结核患者体内的药代动力学特征。

[Translation]

Main purpose: To evaluate the early bactericidal activity of JDB0131 benzenesulfonate tablets in patients with drug-sensitive pulmonary tuberculosis; to explore the optimal effective dose and provide a basis for Phase IIb clinical trials. Secondary objectives: 1. To evaluate the safety and tolerability of JDB0131 benzenesulfonate tablets in patients with drug-sensitive pulmonary tuberculosis after multiple administrations; 2. To evaluate the pharmacokinetic characteristics of JDB0131 benzenesulfonate tablets in patients with drug-sensitive pulmonary tuberculosis after multiple administrations.

Start Date27 Oct 2023

Sponsor / Collaborator

Changzhou Yinsheng Pharmaceutical Co., Ltd

[+1]

CTR20202308 / CompletedPhase 1

WXWH0131 片在中国健康成年受试者中单次和多次给药的安全性、耐受性、药代动力学特征及食物影响的 I 期临床研究

[Translation] Phase I clinical study on the safety, tolerability, pharmacokinetic characteristics and food effects of single and multiple doses of WXWH0131 tablets in healthy adult subjects in China

主要目的：评估中国健康成年受试者空腹条件下单次和多次口服 WXWH0131 片的安全性和耐受性。次要目的： 1、评估中国健康成年受试者空腹条件下单次和多次口服 WXWH0131 片的药代动力学特征。 2、评估进食对中国健康成年受试者单次口服 WXWH0131 片药代动力学的影响。

[Translation]

Primary objective: To evaluate the safety and tolerability of single and multiple oral administration of WXWH0131 tablets in healthy Chinese adult subjects under fasting conditions. Secondary objectives: 1. To evaluate the pharmacokinetic characteristics of single and multiple oral administration of WXWH0131 tablets in healthy Chinese adult subjects under fasting conditions. 2. To evaluate the effect of food intake on the pharmacokinetics of single oral administration of WXWH0131 tablets in healthy Chinese adult subjects.

Start Date25 Jan 2021

Sponsor / Collaborator

Changzhou Yinsheng Pharmaceutical Co., Ltd

[+1]

CTR20170084 / RecruitingPhase 1

福比他韦片在慢性丙肝患者中的多剂量、单次、多次给药的耐受性、药代动力学和药效学Ib期临床试验

[Translation] Phase Ib clinical trial of tolerability, pharmacokinetics and pharmacodynamics of multiple-dose, single-dose and multiple-dose fobitasvir tablets in patients with chronic hepatitis C

评价福比他韦片在慢性丙肝患者中多剂量、单次、多次给药耐受性研究；评价福比他韦片在慢性丙肝患者中多剂量、单次、多次给药药代动力学研究；评价福比他韦片在慢性丙肝患者中多剂量、单次、多次给药的抗病毒活性。

[Translation]

To evaluate the tolerability of multiple-dose, single-dose and multiple-dose fobitasvir tablets in patients with chronic hepatitis C; To evaluate the pharmacokinetic study of multiple-dose, single-dose and multiple-dose fobitasvir tablets in patients with chronic hepatitis C; To evaluate the antiviral activity of multiple-dose, single-dose and multiple-dose fobitasvir tablets in patients with chronic hepatitis C.

Start Date25 Dec 2016

Sponsor / Collaborator

Changzhou Yinsheng Pharmaceutical Co., Ltd

[+1]

100 Clinical Results associated with Changzhou Yinsheng Pharmaceutical Co., Ltd

Login to view more data

0 Patents (Medical) associated with Changzhou Yinsheng Pharmaceutical Co., Ltd

Login to view more data

1

Literatures (Medical) associated with Changzhou Yinsheng Pharmaceutical Co., Ltd

01 Sep 2022·Bioorganic & Medicinal Chemistry Letters

Discovery and preclinical evaluations of JBD0131, a novel nitrodihydro-imidazooxazole anti-tuberculosis agent

Article

Author: Ding, Charles Z ; Bin, Wang ; Jiang, Ning ; Zhu, Yusong ; Wei, Yuquan ; Shen, Liang ; Chen, Shuhui ; Huang, Zhigang ; Wei, Xiawei ; Luo, Wei ; Yang, Meng ; Franzblau, Scott G ; Hu, Yinghu ; Xu, Deming ; Tao, Xin

Multidrug-resistant pulmonary tuberculosis (MDR-TB) is a major health problem worldwide. The treatment for MDR-TB requires medications for a long duration (up to 20-24 months) with second-line drugs resulting in unfavorable outcomes. Nitroimidazoles are promising antimycobacterial agents known to inhibit both aerobic and anaerobic mycobacterial activity. Delamanid and pretomanid are two nitroimidazoles approved by the regulatory agencies for MDR-TB treatment. However, both agents possess unsatisfactory absorption and QTc prolongation. In our search for a safer nitroimidazole, we discovered JBD0131 (2). It exhibited excellent anti-mycobacterial activity against M. tuberculosis H37Rv in vitro and in vivo, improved PK and absorption, reduced QT prolongation potential of delamanid. JBD0131 is currently in clinical development in China for pulmonary tuberculosis (CTR20202308).

100 Deals associated with Changzhou Yinsheng Pharmaceutical Co., Ltd

Login to view more data

100 Translational Medicine associated with Changzhou Yinsheng Pharmaceutical Co., Ltd

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Phase 2 Clinical

Phase 3 Clinical

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Fopitasvir ( NS5A )	Hepatitis C, Chronic More	Phase 3 Clinical
WXWH-0131	Drug-Resistant Tuberculosis More	Phase 2
Amphihevir ( NS4B )	Chronic hepatitis C genotype 1 More	Phase 1